Sahlgrenska University Hospital, Dpt. of Dermatology
Gothenburg, 41345, Sweden
NCT Number: NCT00966173
This is an international, multicenter, prospective, non controlled, non randomized, clinical study to collect electrical impedance data of potentially malignant pigmented nevi and histological diagnoses (International Melanoma Algorithm Training Study [IMATS]). The study objective is to collect data for training and optimization of an algorithm that can classify skin lesions using electrical impedance, i.e., to identify malignant melanomas.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Gothenburg, 41345, Sweden
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Following enrollment, patients will undergo measurements with SciBase III Electrical Impedance Spectrometer. Electrical impedance of the skin will be measured with a microinvasive spiked probe.
Time frame: Q1 2010
SciBase AB
Other
An International, Multicenter, Prospective, Non-controlled, Non-randomised, Clinical Study to Collect Impedance Data of Potentially Malignant Pigmented Nevi and Histological Diagnoses
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03236935
Bronchial Neoplasms, Carcinoma
Houston, Texas, United States
View Trial DetailsNCT07427953
Drug-Induced Retinopathy, Malignant Melanoma
Ljubljana, Slovenia
View Trial DetailsNCT07436390
Malignant Melanoma, Melanoma
Ljubljana, Slovenia
View Trial DetailsNCT07431489
MEK Inhibitor-Associated Retinopathy, Malignant Melanoma
Ljubljana, Slovenia
View Trial Details